N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of £1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to £1.4 million from £1.2 million. Looks ahead to the rest of 2024 with ‘great optimism.’

Chief Executive Nigel Theobald says: ‘2023 was a year of good progress for the company with material advancements in the capabilities of Nuvec both in its ability to dual load and in its potential for oral delivery. We achieved our objective of expanding our portfolio through our interest in Nanogenics which brings us a clear path for taking a product to market and the potential for orphan drug designation.’

Current stock price: 0.82 pence, down 2.9% in London on Tuesday

12-month change: down 57%

Copyright 2024 Alliance News Ltd. All Rights Reserved.